Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-1.59%
|
$218,304
$96.19 P/Share
|
|
Dec 12
2024
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,819
-5.56%
|
$169,167
$93.43 P/Share
|
|
Dec 12
2024
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+8.7%
|
$24,000
$15.01 P/Share
|
|
Nov 29
2024
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,353
-0.51%
|
$225,888
$96.63 P/Share
|
|
Nov 27
2024
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,274
-3.08%
|
$216,030
$95.1 P/Share
|
|
Nov 21
2024
|
Lonnel Coats Director |
SELL
Open market or private sale
|
Direct |
9,824
-81.42%
|
$923,456
$94.87 P/Share
|
|
Nov 20
2024
|
Lonnel Coats Director |
SELL
Open market or private sale
|
Direct |
10,000
-17.41%
|
$940,000
$94.13 P/Share
|
|
Nov 20
2024
|
Lonnel Coats Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,812
+16.08%
|
$643,276
$73.01 P/Share
|
|
Nov 07
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
5,000
-3.08%
|
$510,000
$102.0 P/Share
|
|
Nov 07
2024
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.98%
|
$180,000
$36.05 P/Share
|
|
Oct 03
2024
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
3,633
-5.0%
|
$323,337
$89.32 P/Share
|
|
Sep 09
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
19,702
-5.72%
|
$1,674,670
$85.49 P/Share
|
|
Sep 09
2024
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.34%
|
$360,000
$36.05 P/Share
|
|
Aug 15
2024
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,409
-6.16%
|
$418,855
$95.23 P/Share
|
|
Aug 05
2024
|
Philina Lee Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
41,913
-54.69%
|
$3,897,909
$93.19 P/Share
|
|
Aug 05
2024
|
Philina Lee Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,913
+9.21%
|
$2,472,867
$59.11 P/Share
|
|
Jul 05
2024
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,850
-8.09%
|
$427,350
$111.2 P/Share
|
|
Jul 05
2024
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,850
+7.48%
|
$207,900
$54.13 P/Share
|
|
Jul 03
2024
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
8,817
-16.77%
|
$978,687
$111.29 P/Share
|
|
Jul 03
2024
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,817
+14.36%
|
$476,118
$54.13 P/Share
|
|
Jul 01
2024
|
Christina Rossi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,625
+11.52%
|
-
|
|
Jul 01
2024
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+13.18%
|
-
|
|
Jun 28
2024
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
333
-0.76%
|
$36,963
$111.15 P/Share
|
|
Jun 28
2024
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
333
+0.75%
|
$17,982
$54.13 P/Share
|
|
Jun 21
2024
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
74,034
-16.48%
|
$7,699,536
$104.09 P/Share
|
|
Jun 21
2024
|
Debra Durso Bumpus Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,482
+13.81%
|
$1,874,942
$31.55 P/Share
|
|
Jun 12
2024
|
Jeffrey W. Albers Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+1.32%
|
-
|
|
Jun 12
2024
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+3.72%
|
-
|
|
Jun 12
2024
|
Lynn Seely Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+14.47%
|
-
|
|
Jun 12
2024
|
John Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+20.41%
|
-
|
|
Jun 12
2024
|
Lonnel Coats Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+14.47%
|
-
|
|
Jun 12
2024
|
Daniella Beckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+17.14%
|
-
|
|
Jun 12
2024
|
Habib J Dable Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+20.41%
|
-
|
|
Jun 12
2024
|
Alexis Borisy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+2.93%
|
-
|
|
Jun 12
2024
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+10.94%
|
-
|
|
Jun 05
2024
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-8.72%
|
$420,000
$105.13 P/Share
|
|
Jun 04
2024
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,424
-7.59%
|
$252,096
$104.91 P/Share
|
|
Jun 03
2024
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,436
-5.04%
|
$258,216
$106.43 P/Share
|
|
Jun 03
2024
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,922
-6.91%
|
$521,732
$106.43 P/Share
|
|
May 31
2024
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
34,108
-14.3%
|
$3,615,448
$106.25 P/Share
|
|
May 31
2024
|
L. Becker Hewes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,687
+11.51%
|
$1,382,472
$56.9 P/Share
|
|
May 15
2024
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,850
-2.58%
|
$408,100
$106.86 P/Share
|
|
May 15
2024
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,856
-15.24%
|
$620,736
$106.89 P/Share
|
|
May 15
2024
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,856
+12.47%
|
$228,384
$39.6 P/Share
|
|
May 08
2024
|
Michael Landsittel Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,181
+14.36%
|
$140,905
$5.34 P/Share
|
|
May 02
2024
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-17.46%
|
$1,050,000
$105.0 P/Share
|
|
May 02
2024
|
Michael Landsittel Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.86%
|
$360,000
$36.05 P/Share
|
|
May 02
2024
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,834
-10.95%
|
$188,902
$103.88 P/Share
|
|
May 02
2024
|
Ariel Hurley Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+9.87%
|
$99,036
$54.13 P/Share
|
|
Mar 28
2024
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-9.56%
|
$475,000
$95.0 P/Share
|